Patent classifications
C07C57/145
CO-CRYSTAL OF CARFILZOMIB WITH MALEIC ACID AND PROCESS FOR THE PREPARATION OF PURE CARFILZOMIB
Aspects of the present application relates to co-crystal of carfilzomib with maleic acid, process for the preparation of co-crystal of carfilzomib with maleic acid, process for the preparation of pure carfilzomib from co-crystal of carfilzomib with maleic acid and process for the preparation of amorphous carfilzomib.
WATER-SOLUBLE UNIT DOSE ARTICLES MADE FROM A COMBINATION OF DIFFERENT FILMS
The present disclosure relates to pouches made from a combination of chemically different water-soluble films and optionally containing a composition (e.g. a household care composition or non-household care composition) that is at least partially enclosed by the water-soluble films in at least one compartment.
WATER-SOLUBLE UNIT DOSE ARTICLES MADE FROM A COMBINATION OF DIFFERENT FILMS
The present disclosure relates to pouches made from a combination of chemically different water-soluble films and optionally containing a composition (e.g. a household care composition or non-household care composition) that is at least partially enclosed by the water-soluble films in at least one compartment.
WATER-SOLUBLE UNIT DOSE ARTICLES MADE FROM A COMBINATION OF DIFFERENT FILMS
The present disclosure relates to water-soluble unit dose articles made from a combination of chemically different water-soluble films and optionally containing compositions that are at least partially enclosed by the water-soluble films in at least one compartment.
WATER-SOLUBLE UNIT DOSE ARTICLES MADE FROM A COMBINATION OF DIFFERENT FILMS
The present disclosure relates to water-soluble unit dose articles made from a combination of chemically different water-soluble films and optionally containing compositions that are at least partially enclosed by the water-soluble films in at least one compartment.
CYTISINE SALTS
Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.
CYTISINE SALTS
Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.
WATER-SOLUBLE PACKETS
The disclosure provides a water soluble pouch including at least two sealed compartments, the pouch including outer walls including water soluble film including a water soluble resin, and an inner wall including water soluble film including a water soluble resin, the outer wall films being sealed to the inner wall film, the outer wall films being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the outer wall films having a viscosity in a range of 14.5 cP to 25 cP, and a pouch strength of at least 200 N, and the inner wall film being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the inner film having viscosity in a range of 12 cP to 14.5 cP, and a tackiness value of at least 1500 g/s.
Crystals
A main object of the present invention is to provide new crystals of (S)-N.sup.2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N.sup.6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å).
SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.